Table 2.
Post-baseline treatment, follow-up, and outcomes of cohort by response groups
| All-comers (n = 169) | BM blast-evaluable (n = 95; 56%) | Blast clearance unevaluableb (n = 74; 44%) | |||
|---|---|---|---|---|---|
| BM blast clearance (n = 78) | rwCR/CRh (n = 45)a | Non-response (n = 17) | |||
| 1L regimen | |||||
| Venetoclax + azacitidine | 103 (60.9) | 49 (62.8) | 30 (66.7) | 11 (64.7) | 43 (58.1) |
| Venetoclax + decitabine | 66 (39.1) | 29 (37.2) | 15 (33.3) | 6 (35.3) | 31 (41.9) |
| Transplant (any time during the study period) | |||||
| Yes | 12 (7.1) | 11 (14.1) | 7 (15.6) | 0 (0) | <4 (<5.4) |
| Death in follow-up | 94 (55.6) | 29 (37.2) | 12 (26.7) | 14 (82.4) | 51 (68.9) |
| Death within 60 days | 17 (10.1) | <4 (<5.1) | 0 (0) | <4 (<23.5) | 14 (18.9) |
| Follow-up timec | |||||
| Median (IQR) | 7.2 (3.1−10.5) | 9.6 (6.6−14.2) | 10.5 (7.9−15.6) | 4.6 (3.8−8.6) | 3.7 (2.1−7.8) |
| Min, max | 0.6, 24.8 | 1.9, 24.8 | 2.2, 24.8 | 0.8, 11.4 | 0.6, 19.2 |
All values are n (%) unless otherwise specified. To eliminate the potential to re-identify a patient, any instances where there are fewer than 4 patients have been defined as <4.
rwCR/CRh is a subset of the 78 patients with BM blast clearance; among all the patients with BM clearance, 13 patients had no cell count data within the ±14-day time frame. The remaining BM blast-evaluable patients (n = 17) had a non-response.
Patients who did not have evaluable blast clearance due to a lack of BM data found in their records during follow-up.
Months from treatment initiation to death or censoring.
Abbreviations: 1L, first-line; BM, bone marrow; IQR, interquartile range; max, maximum; min, minimum; rwCR/CRh, real-world complete response/complete response with partial hematologic recovery.